{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-25-000058","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.489117+00:00","generated_at":"2026-05-17T00:07:28.800687+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ligand Q3 revenue $115.5M, net income $117.3M; raises FY guidance","bullets":["Q3 royalties $46.6M, up 47% YoY, driven by Filspari, Ohtuvayre, Qarziba.","Adjusted EPS $3.09 vs $1.84 YoY; GAAP net income $117.3M ($5.68 diluted).","FY 2025 core revenue guidance raised to $225M-$235M; core adj. EPS $7.40-$7.65.","Closed $460M 0.75% convertible notes due 2030; net proceeds ~$445M.","New royalty investments: $7M for AT220/AT292 rights; $25M in Orchestra BioMed."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-25-000058","json":"https://secwatch.observer/filing/0000886163-25-000058.json","markdown":"https://secwatch.observer/filing/0000886163-25-000058.md","text":"https://secwatch.observer/filing/0000886163-25-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616325000058/0000886163-25-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616325000058/lgnd-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:07:28.800687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}